Poor
Not Aligned
Patient Risk:
Moderate
Summary
The provided AI-style statements are largely about gastrointestinal effects and general dosing/treatment changes, but the evaluation claim context is “Risk of Thyroid C-Cell Tumors (including MTC).” The text supplied does not contain thyroid C-cell tumor/MTC risk content supported by the provided label excerpts; instead, it includes unrelated GI and management assertions, leading to substantial misalignment.
Category Scores
Accurate Statements
The FDA has issued a warning regarding gastrointestinal events associated with GLP-1 receptor agonists.
No corresponding GI warning text was provided in the supplied label excerpts (Sections 1, 4, 5.1, 6, 13.1, 17).
Unsupported Statements
Ozempic is used to treat type 2 diabetes.
Not evaluated against the provided label excerpts for this task beyond general indication; however, the supplied label includes type 2 diabetes indications in Section 1, but the requested evaluation focus was thyroid C-cell tumors. This statement is not substantiated within the provided MTC-specific excerpts.
Ozempic can cause stomach pain in some patients.
No gastrointestinal adverse reaction/supporting label text was included in the provided excerpts.
Nausea is a common side effect of Ozempic.
No nausea/common adverse reaction label text was included in the provided excerpts.
Vomiting is a common side effect of Ozempic.
No vomiting/common adverse reaction label text was included in the provided excerpts.
Diarrhea is a common side effect of Ozempic.
No diarrhea/common adverse reaction label text was included in the provided excerpts.
Many patients report stomach pain, bloating, and discomfort associated with Ozempic use.
No patient-reported prevalence data was included in the provided excerpts.
The exact cause of stomach pain with Ozempic use is not fully understood.
No label text provided for the GI mechanism/causal explanation.
Stomach pain with Ozempic use is thought to be related to Ozempic's ability to slow gastric emptying and reduce appetite.
No label text provided for this mechanism.
Slowing gastric emptying and reducing appetite can lead to nausea, vomiting, and abdominal discomfort in some individuals.
No label text provided for this causal chain.
Some patients have reported stomach pain and other gastrointestinal issues after starting Ozempic.
No postmarketing timing/reporting details were included in the provided excerpts.
Nearly 20% of respondents experienced stomach pain or discomfort while taking Ozempic.
No numeric incidence/statistic was included in the provided excerpts.
Taking Ozempic with food may minimize stomach pain associated with Ozempic.
No administration-with-food guidance for minimizing GI pain was included in the provided excerpts.
Patients may need to adjust their dosage or switch to a different medication for better symptom management.
No dosage adjustment/switching guidance was included in the provided excerpts.
Contradictions
Important Omissions
Statements specifically addressing the FDA-labeled Risk of Thyroid C-Cell Tumors (including MTC), such as semaglutide-induced thyroid C-cell tumors in rodents, human relevance unknown, contraindication in patients with personal/family history of MTC or MEN 2, and patient counseling about thyroid tumor symptoms and monitoring value uncertainty.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The content provided does not cover the label’s thyroid C-cell tumor risk elements (including contraindication) that are central to the evaluated claim context, and instead emphasizes unrelated GI effects without label support from the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The AI response content is not aligned with the evaluated FDA label claim (thyroid C-cell tumors/MTC). It lacks the required warning/contraindication elements and instead discusses GI adverse effects without label support from the provided excerpts.
Suggested Improvement
Include on-label thyroid C-cell tumor/MTC statements from Sections 4 and 5.1 (rodent findings, human relevance unknown, contraindication in personal/family history of MTC or MEN 2, and symptom counseling/uncertain value of routine calcitonin/ultrasound monitoring as applicable). Remove or clearly separate unrelated GI prevalence/management assertions unless supported by the provided labeling text.